세계의 희귀 신장 질환 시장 : 표적 적응증별, 분자 유형별, 생물 제제 유형별, 투여 경로별, 치료 유형별, 주요 지역별, 주요 의약품 개발 기업별, 매출 예측 업계 동향 및 예측(-2040년)

Rare Kidney Diseases Market by Target Disease Indications, Type of Biologics, Route of Administration, Type of Therapy, Key Geographical Regions, Leading Drug Developers and Sales Forecast: Industry Trends and Global Forecasts, Till 2040

US $ 4,799 ￦ 6,606,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,635,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,591,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 24,779,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

희귀 신장 질환 시장

세계의 희귀 신장 질환 시장 규모는 2024년에 22억 달러에 달했습니다. 이 시장은 현재 28억 달러로 2035년에 116억 달러에 달할 전망이며, 예측 기간 중 CAGR 15.2%로 성장이 전망됩니다.

희귀 신장 질환 시장의 기회는 다음 부문에 분포되어 있습니다.

표적 적응증

• 비정형 용혈성 요독 증후군
• 패브리병
• 둥근 국소 분절 사구체 경화증(FSGS)
• 면역글로불린A신증
• 루푸스 신염
• 기타

분자형

• 생물 제제
• 저분자

생물 제제 유형

• 효소
• 호르몬
• 단일클론항체
• 단백질

투여 경로

• 정맥내
• 경구
• 피하

치료 유형

• 단제요법
• 병용 요법

주요 지역

• 북미
• 유럽
• 아시아태평양

희귀 신장 질환 시장 : 성장 및 동향

신장 질환에는 혈액에서 노폐물과 여분의 수분을 효율적으로 여과하는 신장 본래의 기능을 방해하는 다양한 질환이 포함됩니다. 이러한 질환은 또한 혈압을 조절하고 체내의 전체적인 수분 밸런스를 유지하는 신장의 기능 전반을 손상시킵니다. 특히 신장 질환은 초기 단계에서는 자각 증상이 없는 경우가 많아 진단이 어렵습니다. 하지만 노폐물이 체내에 축적되면 고혈압, 빈혈, 영양불량, 신경장애 등의 증상이 나타날 수 있습니다. 미국 질병예방통제센터에 따르면 2024년에는 미국에서 약 3,550만 명이 신장 질환에 이환될 것으로 추정되며, 전체 인구의 14% 가까이를 차지하고 있습니다. 이러한 질환의 일부인 희귀 신장 질환은 세계적으로 볼 때 극히 일부 사람에게만 이환되고 있습니다. 희귀 병용 의약품법(Orphan Drug Act)에 따라 미국에서는 이 환자 수가 20만 명 미만이면 희귀병으로 분류됩니다. 그러나 유럽연합(EU)에서는 희귀 질환은 유럽인 1만 명당 약 5명이 이환되는 질환으로 정의되고 있습니다.

희귀 신장 질환은 주로 신장 여과 장치(사구체로 알려진)에 영향을 미치며 소변에 단백질 성분과 혈액이 유출됩니다. 이러한 질환은 선천성, 후천성, 유전성인 것이 있어 진단이나 치료를 위한 특정 바이오마커를 동정하는 것이 어렵습니다. 적시의 개입이 없으면 드문 신장 질환은 종종 신부전에 이르러 투석이나 이식이 필요합니다. 희귀한 만성신질환으로 인한 신부전은 신장 질환을 앓는 소아의 최소 5명 중 3명, 성인의 9명 중 1명에게 인정되고 있는 것은 중요합니다. 이러한 과제에 대처하기 위해 희귀 신장 질환의 진단과 치료에 있어 큰 진보가 이루어지고 있습니다. 유전자 배열 결정이나 맞춤형 치료 등의 정밀 치료에 의해, 이러한 질환의 표적 치료가 가능하게 되어 있습니다. 게다가 빅데이터 및 머신러닝의 통합은 임상시험을 위한 환자 모집을 개선하고 맞춤형 치료를 위한 정확한 소변 바이오마커를 특정함으로써 몇몇 의약품 개발자와 연구자들을 지원하고 있습니다.

게다가 관민 양부문으로부터 다액의 투자가 이 영역의 연구개발을 가속시키고 있습니다. 현재 의약품 개발 기업은 희귀 신장 연구와 치료 개발을 위해 120억 달러가 넘는 자금을 확보하고 있습니다. 게다가 효율적인 진단 및 치료에 대한 주목이 높아지는 가운데, 희귀 신장 질환 치료제 및 치료 시장은 강력한 성장을 이루어 향후 몇 년간, 이해 관계자에게 큰 기회를 제공할 태세가 갖추어져 있습니다.

희귀 신장 질환 시장 : 주요 인사이트

이 보고서는 희귀 신장 질환 시장의 현재 상태를 파악하고 업계의 잠재적 성장 기회를 확인합니다. 본 보고서의 주요 조사 결과는 다음과 같습니다. :

• 희귀 신장 질환 치료제 및 치료법의 70% 이상이 임상개발 단계에 있습니다. 특히 면역글로불린 A 신증이나 루푸스 신염의 치료제 및 치료법의 대부분이 연구되고 있습니다.

• 이 영역에 대한 관심이 높아지고 있는 것은 과거에 다양한 이해 관계자간에 맺어진 파트너십의 여러가지로 보아, 실제 거래 전체의 65%가 과거 3년간 맺어졌습니다.
• 이 분야의 기회를 깨달은 여러 투자자가 다양한 자금 조달 라운드를 통해 다액의 자금을 투자하고 있으며, 이 분야에 대한 투자의 45%는 판매를 통해 이루어졌습니다.
• 희귀 신장 질환을 표적으로 하는 약제의 40% 가까이가, 현재 임상 개발의 제II상 단계에 있습니다.

• 희귀 신장 질환 시장은 2035년까지 연률 15%(CAGR)로 성장할 전망이며, 2035년까지 시장 점유율의 대부분(-70%)을 북미가 차지할 것으로 예상되고 있습니다.

• 현재, 단일클론항체가 시장을 독점하고 있지만, 특히 경구 투여가 2035년까지 시장의 대부분을 차지할 것으로 예측됩니다.

희귀 신장 질환 시장 : 주요 부문

세계의 희귀 신장 질환 시장은 표적 적응증별로는 비정형 용혈성 요독 증후군, 패브리병, 둥근 국소 분절 사구체 경화증(FSGS), 면역글로불린 A 신증, 루푸스 신염, 기타로 구분됩니다. 현재 희귀 신장 질환 시장의 대부분의 점유율을 차지하고 있는 것은 루푸스 신염입니다. 이는 환자 집단과 헬스케어 전문가 모두에서 이 질환의 위험성에 관한 인식이 높아지고 있기 때문입니다.

분자 유형별로 세계 시장은 저분자와 생물 제제로 구분됩니다. 이러한 유형 중에서 저분자 부문은 현재 시장 전체에서 최대의 점유율을 차지하고 있습니다. 그러나 생물 제제는 희귀 신장 질환과 관련된 근본적인 생물학적 경로를 표적으로 할 수 있는 유망한 대체품으로 대두되며, 따라서 향후 수년간 더 큰 시장 점유율을 획득할 것으로 기대되고 있음에 유의하는 것이 중요합니다.

생물 제제 유형별로는 세계 시장 규모는 효소, 호르몬, 단일클론항체, 단백질로 구분됩니다. 주목할 만한 것은 단일클론항체 부문이 현재 시장을 독점하고 있다는 것입니다. 또한 이 동향은 희귀 신장 질환 치료에 있어 그 정확도가 실증되고 있기 때문에 앞으로도 변하지 않을 것으로 생각됩니다.

투여 경로별로 세계 시장은 정맥내 투여, 경구 투여, 피하 투여로 구분됩니다. 현재 경구 투여 경로는 다른 경로에 비해 비침습적이며, 환자의 컴플라이언스가 향상됨에 따라 희귀 신장 질환 시장의 대부분을 차지할 것으로 예상됩니다. 그러나 이 경향은 예측 기간 동안 변화했으며, 향후 수년간은 피하 투여 경로가 시장 전체의 더 큰 점유율을 차지할 것으로 예상된다는 점은 특기할 만합니다.

치료 유형별로 세계의 희귀 신장 질환 시장은 단일 요법과 병용 요법으로 구분됩니다. 현재 단일 요법 부문이 시장 전체에서 가장 큰 점유율을 차지하고 있습니다. 그러나 병용 요법 시장은 예측 기간 동안 상대적으로 높은 CAGR로 성장할 가능성이 높습니다.

주요 지역별로 보면 시장은 북미, 유럽, 아시아태평양으로 구분됩니다. 현재 북미가 최대 시장 점유율을 차지하고 있습니다. 그러나 중국, 일본, 한국, 인도 등 아시아 국가에서는 희귀 신장 질환의 이환율이 증가하고 있으며, 이 지역에서는 보다 효과적인 치료 관리 시스템이 필요하기 때문에 아태지역 시장은 예측 기간 동안 보다 빠른 속도로 성장할 것으로 예상됩니다.

이 보고서에서 대답하는 주요 질문

• 현재, 이 시장에는 몇사가 참가하고 있는지
• 이 시장의 주요 기업
• 이 시장의 진화에 영향을 줄 것 같은 요인
• 현재 및 미래 시장 규모
• 이 시장의 CAGR
• 현재 및 미래 시장 기회는 주요 시장 부문에 어떻게 분배될 것인가
• 시장에서의 특허 출원 동향

이 보고서를 구입하는 이유

• 이 보고서는 종합적인 시장 분석을 제공하며 전체 시장 및 특정 하위 부문에 대한 자세한 수익 예측을 제공합니다. 이 정보는 이미 시장을 선도하는 기업과 신규 진출기업 모두에게 귀중합니다.
• 이해관계자는 시장 내 경쟁 역학을 보다 깊이 이해하기 위해 보고서를 활용할 수 있습니다. 경쟁 구도를 분석함으로써 기업은 시장에서의 포지셔닝을 최적화하고 효과적인 시장 진출 전략을 개발하기 위해 정보를 기반으로 의사 결정을 내릴 수 있습니다.
• 본 보고서는 주요 촉진요인 및 시장 억제요인과 과제를 포함한 시장의 종합적인 개요를 이해관계자에게 제공합니다. 이 정보는 이해관계자가 시장 동향을 항상 파악하고 성장 전망을 활용하기 위한 데이터 주도의 의사 결정을 할 수 있는 힘이 됩니다.

기타 혜택

• 무료 엑셀 데이터 팩
• 10% 무료 컨텐츠 커스터마이즈
• 조사팀에 의한 상세 보고서의 워크스루 세션
• 보고서가 6-12개월 이상 전인 경우, 무료 갱신 보고서

본 보고서에서는 세계의 희귀 신장 질환 시장에 대해 조사했으며, 시장 개요와 함께 표적 적응증별, 분자 유형별, 생물 제제 유형별, 투여 경로별, 치료 유형별, 주요 지역별, 주요 의약품 개발 기업별 동향, 시장 진출 기업 프로파일 등의 정보를 제공합니다.

목차

섹션 I : 보고서 개요

제1장 배경

제2장 조사 방법

제3장 시장 역학

제4장 거시경제지표

섹션 II : 질적 인사이트

제5장 주요 요약

제6장 서문

• 신장 질환의 개요
• 희귀 신장 질환 치료 표적의 선택
• 희귀 신장 질환 영역에서의 기술 진보
• 희귀 신장 질환 영역에서의 최근 동향
• 장래의 전망

섹션 III : 경쟁 구도

제7장 시장 상황

제8장 기업 경쟁력 분석

섹션 VI : 기업 프로파일

제9장 희귀 신장 질환 시장 : 북미에 거점을 두는 의약품 및 치료법 개발 기업의 기업 프로파일

• 장의 개요
• Alexion Pharmaceuticals
• Biogen
• NovelMed
• Travere Therapeutics
• Vertex Pharmaceuticals
• Amgen
• Vera Therapeutics
• ZyVersa Therapeutics

제10장 희귀 신장 질환 시장 : 유럽에 거점을 두는 의약품 및 치료법 개발 기업의 기업 프로파일

• 장의 개요
• Novartis
• Roche
• Advicenne
• Boehringer Ingelheim
• Calliditas Therapeutics

제11장 희귀 신장 질환 시장 : 아시아태평양에 거점을 두는 의약품 및 치료법 개발 기업의 기업 프로파일

• 장의 개요
• Jiangsu Hengrui Pharmaceuticals
• Asahi Kasei

섹션 V : 시장 동향

제12장 파트너십 및 협업

• 파트너십 모델
• 희귀 신장 질환의 의약품 및 치료법 : 파트너십 및 협력

제13장 자금조달 및 투자

• 자금 조달 모델
• 자금 조달 라이프 사이클 분석
• 투자 사례 : 리스크 및 리턴
• 희귀 신장 질환의 의약품 및 치료법 : 자금 조달 및 투자
• 투자 요약

제14장 임상시험 분석

• 조사 방법 및 주요 파라미터
• 희귀 신장 질환의 의약품 및 치료법 : 임상시험 분석

제15장 임상적 상업적 매력

• 조사 방법 및 주요 파라미터
• 득점
• 희귀 신장 질환을 표적으로 한 제III상 의약품 및 치료법

제16장 KOL(Key Opinion Leader)

제17장 희귀 신장 질환 시장 : 사례 연구

섹션 VI : 시장 예측 및 기회 분석

제18장 시장 영향 분석 : 촉진요인, 억제요인, 기회, 과제

• 장의 개요
• 시장 성장 촉진요인
• 시장 성장 억제요인
• 시장 기회
• 시장 과제
• 결론

제19장 희귀 신장 질환시장

• 주요 전제 및 조사 방법
• 세계의 희귀 신장 질환 시장 : 과거 동향 및 예측(-2040년)
• 주요 시장 세분화

제20장 희귀 신장 질환 시장 : 표적 적응증별

제21장 희귀 신장 질환 시장 : 분자 유형별

제22장 희귀 신장 질환 시장 : 생물 제제 유형별

제23장 희귀 신장 질환 시장 : 투여 경로별

제24장 희귀 신장 질환 시장 : 치료 유형별

제25장 희귀 신장 질환 시장 : 주요 지역별

제26장 희귀 신장 질환 시장 : 의약품 매출 예측

제27장 희귀 신장 질환 시장 : 주요 의약품 개발 기업별

섹션 VII : 기타 독점 인사이트

제28장 결론

제29장 1차 조사로부터의 인사이트

섹션 VIII : 부록

제30장 표 형식 데이터

제31장 기업 및 단체 일람

AJY

영문 목차

영문목차

RARE KIDNEY DISEASES MARKET

As per Roots Analysis, the global rare kidney diseases market size is valued at USD 2.2 billion in 2024 and is projected to reach USD 2.8 billion in the current year and USD 11. 6 billion by 2035, growing at a CAGR of 15.2% during the forecast period.

The opportunity for rare kidney diseases market has been distributed across the following segments:

Target Disease Indications

• Atypical Hemolytic Uremic Syndrome
• Fabry Disease
• Focal Segmental Glomerulosclerosis
• Immunoglobulin A Nephropathy
• Lupus Nephritis
• Others

Type of Molecule

• Biologics
• Small Molecules

Type of Biologic

• Enzymes
• Hormones
• Monoclonal Antibodies
• Proteins

Route of Administration

• Intravenous
• Oral
• Subcutaneous

Type of Therapy

• Monotherapy
• Combination Therapy

Key Geographical Regions

• North America
• Europe
• Asia-Pacific

RARE KIDNEY DISEASES MARKET: GROWTH AND TRENDS

Kidney diseases include a wide array of conditions that hinder the natural ability of the kidney to efficiently filter waste and excess fluid from the blood. These diseases also compromise the overall function of the kidneys to regulate blood pressure and maintain the overall fluid balance in the body. Notably, in the early stages, kidney diseases often present no symptoms, making the diagnosis challenging. However, as waste accumulates in the body, patients may experience symptoms, such as high blood pressure, anemia, poor nutritional health and nerve damage. According to the US Centers for Disease Control and Prevention, approximately 35.5 million people in the US were estimated to be affected by kidney diseases, in 2024, accounting for nearly 14% of the overall population. A subset of these conditions, rare kidney diseases, affect a smaller fraction of individuals worldwide. Under the Orphan Drug Act, a disease is classified as rare in the US if it affects less than 200,000 people. However, in the European Union, rare diseases are defined as those impacting around 5 per 10,000 Europeans.

Rare kidney diseases primarily affect the kidneys' filtering units (known as glomeruli), leading to the spillage of protein components and blood into the urine. These conditions can either be congenital, acquired or inherited, making it difficult to identify specific biomarkers for diagnosis and treatment. Without timely intervention, rare kidney diseases often lead to kidney failure, necessitating dialysis or transplantation. It is important to mention that kidney failure due to a rare chronic kidney disease has been observed in at least 3 out of 5 children and 1 in 9 adults suffering from kidney diseases. To address these challenges, significant advancements have been made in diagnosing and treating rare kidney diseases. Precision medicines, including genomic sequencing and personalized therapies, have enabled the targeted treatment of these diseases. Additionally, the integration of big data and machine learning has helped several drug developers and researchers by improving patient recruitment for clinical trials and identifying accurate urinary biomarkers for tailored treatment.

Moreover, substantial investment from both public and private sectors accelerates research and development in this domain. Presently, drug developers have secured over USD 12 billion in funding for rare kidney research and treatment development. Further, with a growing focus on efficient diagnosis and treatment, the market for rare kidney disease drugs / therapies is poised for robust growth, presenting significant opportunities for stakeholders in the coming years.

RARE KIDNEY DISEASES MARKET: KEY INSIGHTS

The report delves into the current state of the rare kidney diseases market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• Over 70% of the rare kidney drugs / therapies are in clinical stages of development; notably, most of the drugs / therapies are being investigated for the treatment of immunoglobulin A nephropathy and lupus nephritis.

• The rising interest in this domain is evident from the wide array of partnerships established between various stakeholders in the recent past; in fact, 65% of the total deals were inked in the last three years.
• Several investors, having realized the opportunity within this domain, have invested significant capital across various funding rounds; 45% of the investments in this domain were made through secondary offerings.
• Nearly 40% of the drugs targeting rare kidney diseases are currently in Phase II of clinical development; notably, around 60% of the trials have been sponsored by industry players.

• The rare kidney disease market is likely to grow at an annualized rate (CAGR) of ~15%, till 2035; the majority of the market share (~70%) is expected to be captured by North America, by 2035.

• Currently, the monoclonal antibodies dominate the market; notably, oral route of administration is anticipated to capture the majority share in the market by 2035.

RARE KIDNEY DISEASES MARKET: KEY SEGMENTS

Lupus Nephritis is the Fastest Growing Segment in the Rare Kidney Diseases Market

Based on the type of target disease indication, the global rare kidney disease market is segmented into atypical hemolytic uremic syndrome, Fabry disease, focal segmental glomerulosclerosis, immunoglobulin A nephropathy, lupus nephritis, and others. Currently, the majority share of the rare kidney disease market is captured by lupus nephritis, due to the increasing awareness regarding the adversity of the disease among both patient population and healthcare professionals.

Small Molecules are Likely to Hold the Largest Share of the Rare Kidney Diseases Market During the Forecast Period

Based on the type of molecule, the global market is segmented into small molecules and biologics. Amongst these types, the small molecules segment occupies the largest share of the current overall market. However, it is important to note that biologics are expected to emerge as a promising alternative that can target underlying biological pathways associated with rare kidney disease, therefore, capturing a larger market share in the coming years.

Rare Kidney Diseases Market for Proteins is Likely to Grow at a Relatively Faster Pace During the Forecast Period

Based on the type of biologic, the global market value is segmented across enzymes, hormones, monoclonal antibodies, and proteins. Notably, the monoclonal antibodies segment dominates the current market. Moreover, this trend is unlikely to change in the foreseen future owing to their proven precision in treating rare kidney diseases.

Oral Route of Administration Holds the Largest Share of the Rare Kidney Diseases Market

Based on the route of administration, the global market is segmented across intravenous, oral and subcutaneous routes of administration. Currently, the oral route is expected to hold the majority rare kidney disease market share owing to its non-invasive nature and increased patient compliance as compared to other routes. However, it is worth mentioning that this trend is expected to change during the forecast period, with the subcutaneous route of administration capturing a larger share of the overall market in the coming years.

By Type of Therapy, Monotherapy Segment is Likely to Dominate the Market During the Forecast Period

Based on the type of therapy, the global market for rare kidney diseases is segmented across monotherapy and combination therapy. At present, the monotherapy segment holds the maximum share in the overall market. However, the market for combination therapy is likely to grow at a relatively higher CAGR during the forecast period.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, and Asia-Pacific. In the current scenario, North America is likely to capture the largest market share. However, the market in Asia-Pacific is expected to grow at a faster pace during the forecast period owing to the fact that various Asian countries, such as China, Japan, Korea, and India are reporting increasing incidence rates of rare kidney diseases which necessitates more effective treatment management systems in this region.

Example Players in the Rare Kidney Diseases Market

• Alexion Pharmaceuticals
• Amicus Therapeutics
• Apellis Pharmaceuticals
• Aurinia Pharmaceuticals
• GlaxoSmithKline
• Novartis
• Roche
• Travere Therapeutics
• Vera Therapeutics

RARE KIDNEY DISEASES MARKET: RESEARCH COVERAGE

The report on Rare Kidney Diseases Market features insights into various sections, including:

• Market Sizing and Opportunity Analysis: An in-depth analysis of the rare kidney diseases market, focusing on key market segments, including [A] type of disease indication, [B] type of molecule, [C] type of biologic, [D] route of administration, [E] type of therapy, [F] key geographical regions, and [G] key players.
• Market Impact Analysis: A thorough analysis of various factors, such as drivers, restraints, opportunities, and existing challenges that are likely to impact market growth.
• Market Landscape: A comprehensive evaluation of rare kidney diseases drugs / therapies developers, based on several relevant parameters, such as [A] stage of development, [B] target indication, [C] route of administration, [D] type of molecule, [E] type of biologic, [F] dosing frequency, [G] target patient population, and [H] type of therapy.
• Rare Kidney Diseases Drug / Therapies Developer Landscape: The report features a list of leading players engaged in the rare kidney diseases domain, along with analyses based on [A] year of establishment, [B] company size, [C] location of headquarters, and [D] most active players (in terms of number of drugs / therapies developed).
• Company Competitiveness Analysis: An insightful competitiveness analysis of the companies engaged in the rare kidney diseases domain, based on various relevant parameters, such as [A] company strength, [B] portfolio strength, and [C] pipeline diversity.
• Company Profiles: In-depth profiles of key industry players offering rare kidney drugs / therapies across various geographies, focusing on [A] company overviews, [B] drug portfolio, [C] financial information (if available), [D] recent developments and [E] an informed future outlook.
• Partnerships and Collaborations: A detailed analysis of partnerships inked between stakeholders in the rare kidney diseases market, since 2019, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] target disease indication, [D] type of partner, [E] most active players (in terms of number of partnerships), and [F] geography.
• Funding and Investments Analysis: A detailed analysis of the various funding and investments raised in the rare kidney diseases domain, based on several relevant parameters, such as [A] year of funding, [B] type of funding, [C] amount of funding, [D] target disease indication, [E] geography, and [F] most active players (in terms of number of funding instances).
• Clinical Trial Analysis: An in-depth analysis of completed / ongoing clinical trials related to rare kidney diseases drugs / therapies, based on various relevant parameters, such as [A] trial registration year, [B] trial status, [C] number of patients enrolled, [D] trial phase, [E] study design (type of trial masking, type of intervention model, trial purpose and design allocation), [F] type of sponsor, [G] patient gender, [H] most active sponsor / collaborator (leading industry and non-industry players based on the number of registered trials), and [I] geography.
• Clinical Commercial Attractiveness: A detailed analysis of the clinical and commercial attractiveness for phase III drugs / therapies targeting rare kidney diseases, based on several parameters, such as [A] type of molecule, [B] dosing frequency, [C] route of administration, [D] number of patients enrolled, [E] company size, [F] patient population, and [G] location of clinical trials.
• KOL Analysis: An insightful analysis, highlighting the key opinion leaders investigating the clinical trials related to rare kidney diseases, based on several parameters, such as [A] type of KOL, [B] qualification, [C] type of organization, [D] geographical location of KOLs, [E] target disease indication, and [F] most prominent KOLs (based on our proprietary and third-party scoring criteria).
• Case Study: An insightful case study highlighting the developers engaged in offering kidney care services, along with information on [A] year of establishment, [B] company size, [C] location of headquarters, [D] target indications, [E] benefits offered by the kidney care companies, and [F] recent developments in the domain.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?
• What is the patent filing activity trend in the market?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary Excel Data Packs
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

SECTION I: REPORT OVERVIEW

1. BACKGROUND

• 1.1. Context
• 1.2. Project Objectives

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross Border Dynamics
• 4.3. Conclusion

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

• 6.1. Overview of Kidney Diseases
  • 6.1.1. Key Historical Events related to Kidney Diseases
  • 6.1.2. Factors Contributing to the Onset of Kidney Diseases
• 6.2. Selection of Therapeutic Targets for Rare Kidney Diseases
• 6.3. Technological Advancements in the Rare Kidney Diseases Domain
• 6.4. Recent Developments in the Rare Kidney Diseases Domain
• 6.5. Future Perspectives

SECTION III: COMPETITIVE LANDSCAPE

7. MARKET LANDSCAPE

• 7.1. Rare Kidney Disease Drugs / Therapies: Market Landscape
  • 7.1.1. Analysis by Stage of Development
  • 7.1.2. Analysis by Target Indication
  • 7.1.3. Analysis by Route of Administration
  • 7.1.4. Analysis by Type of Molecule
  • 7.1.5. Analysis by Type of Biologic
  • 7.1.6. Analysis by Dosing Frequency
  • 7.1.7. Analysis by Target Patient Population
  • 7.1.8. Analysis by Type of Therapy
• 7.2. Rare Kidney Disease Drugs / Therapies: Developer Landscape
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Company Size
  • 7.2.3. Analysis by Location of Headquarters
  • 7.2.4. Analysis by Company Size and Location of Headquarters
  • 7.2.5. Most Active Players: Analysis by Number of Drugs / Therapies Developed

8. COMPANY COMPETITIVENESS ANALYSIS

• 8.1 Methodology and Key Parameters
• 8.2. Scoring
• 8.3. Peer Groups
  • 8.3.1. Overview of Developers based in North America
    • 8.3.1.1. Competitiveness Analysis of Players based in North America
    • 8.3.1.2. Leading Players based in North America
  • 8.3.2. Overview of Developers based in Europe
    • 8.3.2.1. Competitiveness Analysis of Players based in Europe
    • 8.3.2.2. Leading Players based in Europe
  • 8.3.3. Overview of Developers based in Asia-Pacific and Rest of the World
    • 8.3.3.1. Competitiveness Analysis of Players based in Asia-Pacific and Rest of the World
    • 8.3.3.2. Leading Players based in Asia-Pacific and Rest of the World

SECTION IV: COMPANY PROFILES

9. RARE KIDNEY DISEASE MARKET: COMPANY PROFILES OF DRUG / THERAPY DEVELOPERS BASED IN NORTH AMERICA

• 9.1. Chapter Overview
• 9.2. Alexion Pharmaceuticals
  • 9.2.1. Company Details
  • 9.2.2. Drug Portfolio
  • 9.2.3. Financial Details
  • 9.2.4. Recent Developments and Future Outlook
• 9.3. Biogen
  • 9.3.1. Company Details
  • 9.3.2. Drug Portfolio
  • 9.3.3. Financial Details
  • 9.3.4. Recent Developments and Future Outlook
• 9.4. NovelMed
  • 9.4.1. Company Details
  • 9.4.2. Drug Portfolio
  • 9.4.3. Recent Developments and Future Outlook
• 9.5. Travere Therapeutics
  • 9.5.1. Company Details
  • 9.5.2. Drug Portfolio
  • 9.5.3. Financial Details
  • 9.5.4. Recent Developments and Future Outlook
• 9.6. Vertex Pharmaceuticals
  • 9.6.1. Company Details
  • 9.6.2. Drug Portfolio
  • 9.6.3. Financial Details
  • 9.6.4. Recent Developments and Future Outlook
• 9.7. Amgen
  • 9.7.1. Company Details
  • 9.7.2. Drug Portfolio
• 9.8. Vera Therapeutics
  • 9.8.1. Company Details
  • 9.8.2. Drug Portfolio
• 9.9. ZyVersa Therapeutics
  • 9.9.1. Company Details
  • 9.9.2. Drug Portfolio

10. RARE KIDNEY DISEASE MARKET: COMPANY PROFILES OF DRUG / THERAPY DEVELOPERS BASED IN EUROPE

• 10.1. Chapter Overview
• 10.2. Novartis
  • 10.2.1. Company Details
  • 10.2.2. Drug Portfolio
  • 10.2.3. Financial Details
  • 10.2.4. Recent Developments and Future Outlook
• 10.3. Roche
  • 10.3.1. Company Details
  • 10.3.2. Drug Portfolio
  • 10.3.3. Financial Details
  • 10.3.4. Recent Developments and Future Outlook
• 10.4. Advicenne
  • 10.4.1. Company Details
  • 10.4.2. Drug Portfolio
• 10.5. Boehringer Ingelheim
  • 10.5.1. Company Details
  • 10.5.2. Drug Portfolio
• 10.6. Calliditas Therapeutics
  • 10.6.1. Company Details
  • 10.6.2. Drug Portfolio

11. RARE KIDNEY DISEASE MARKET: COMPANY PROFILES OF DRUG / THERAPY DEVELOPERS BASED IN ASIA-PACIFIC

• 11.1. Chapter Overview
• 11.2. Jiangsu Hengrui Pharmaceuticals
  • 11.2.1. Company Details
  • 11.2.2. Drug Portfolio
  • 11.2.3. Recent Developments and Future Outlook
• 11.2. Asahi Kasei
  • 11.2.1. Company Details
  • 11.2.2. Drug Portfolio

SECTION V: MARKET TRENDS

12. PARTNERSHIPS AND COLLABORATIONS

• 12.1. Partnership Models
• 12.2. Rare Kidney Disease Drugs / Therapies: Partnerships and Collaborations
  • 12.2.1. Analysis by Year of Partnership
  • 12.2.2. Analysis by Type of Partnership
  • 12.2.3. Analysis by Year and Type of Partnership
  • 12.2.4. Analysis by Target Disease Indication
  • 12.2.5. Analysis by Type of Partner
  • 12.2.6. Most Active Players: Analysis by Number of Partnerships
  • 12.2.7. Local and International Deals
  • 12.2.8. Intercontinental and Intracontinental Deals

13. FUNDING AND INVESTMENTS

• 13.1. Funding Models
• 13.2. Funding Lifecycle Analysis
• 13.3. Investment Case: Risk and Return
• 13.4. Rare Kidney Disease Drugs / Therapies: Funding and Investments
  • 13.4.1. Analysis of Funding Instances by Year of Funding
  • 13.4.2. Analysis of Funding Instances by Type of Funding
  • 13.4.3. Analysis of Funding Instances by Year and Type of Funding
  • 13.4.4. Analysis of Amount Invested by Year of Funding
  • 13.4.5. Analysis of Amount Invested by Type of Funding
  • 13.4.6. Analysis of Amount Invested by Year and Type of Funding
  • 13.4.7. Analysis of Funding Instances by Target Disease Indication
  • 13.4.8. Analysis of Funding Instances by Geography (Region)
  • 13.4.9. Analysis of Funding Instances by Geography (Country)
  • 13.4.10. Most Active Players: Analysis by Number of Funding Instances
  • 13.4.11. Most Active Players: Analysis by Amount Invested
  • 13.4.12. Leading Investors: Analysis by Number of Funding Instances
• 13.5. Summary of Investments

14. CLINICAL TRIAL ANALYSIS

• 14.1. Methodology and Key Parameters
• 14.2. Rare Kidney Disease Drugs / Therapies: Clinical Trial Analysis
  • 14.2.1. Analysis by Trial Registration Year
  • 14.2.2. Analysis by Trial Status
  • 14.2.3. Analysis by Trial Registration Year and Trial Status
  • 14.2.4. Analysis by Trial Registration Year and Patients Enrolled
  • 14.2.5. Analysis by Trial Status and Patients Enrolled
  • 14.2.6. Analysis by Trial Phase
  • 14.2.7. Analysis by Patients Enrolled and Trial Phase
  • 14.2.8. Analysis by Study Design
  • 14.2.9. Analysis by Type of Sponsor
  • 14.2.10. Analysis by Patient Gender
  • 14.2.11. Most Active Industry Players: Analysis by Number of Trials
  • 14.2.12. Most Active Non-Industry Players: Analysis by Number of Trials
  • 14.2.13. Analysis by Geography
    • 14.2.13.1. Analysis by Trial Status, Trial Phase and Geography
    • 14.2.13.2. Analysis by Trial Status and Geography
  • 14.2.14. Geographical Distribution of Trials and Number of Patients Enrolled
    • 14.2.14.1. Clinical Trials in North America: Key Insights
    • 14.2.14.2. Clinical Trials in Europe: Key Insights
    • 14.2.14.3. Clinical Trials in Asia-Pacific: Key Insights
    • 14.2.14.4. Clinical Trials in Rest of the World: Key Insights

15. CLINICAL COMMERCIAL ATTRACTIVENESS

• 15.1. Methodology and Key Parameters
• 15.2. Scoring
• 15.3. Phase III Drugs / Therapies Targeting Rare Kidney Diseases

16. KEY OPINION LEADERS

• 16.1. Methodology and Key Parameters
• 16.2. Rare Kidney Disease Drugs / Therapies: Key Opinion Leaders
  • 16.2.1. Analysis by Type of Key Opinion Leader
  • 16.2.2. Analysis by Qualification
  • 16.2.3. Analysis by Type of Organization
  • 16.2.4. Analysis by Target Disease Indication
  • 16.2.5. Analysis by Region of Key Opinion Leaders
• 16.3. Scoring Criteria
  • 16.3.1. Most Prominent Key Opinion Leaders
  • 16.3.2. Benchmarking: Roots Analysis' Assessment vs Third Party Scores

17. RARE KIDNEY DISEASE MARKET: CASE STUDY

• 17.1. Methodology
• 17.2. Rare Kidney Disease Market: List of Kidney Care Companies
• 17.3. Benefits Offered by Kidney Care Companies
• 17.4. Recent Developments

SECTION VI: MARKET FORECAST AND OPPORTUNITY ANALYSIS

18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 18.1. Chapter Overview
• 18.2. Market Drivers
• 18.3. Market Restraints
• 18.4. Market Opportunities
• 18.5. Market Challenges
• 18.6. Conclusion

19. RARE KIDNEY DISEASE MARKET

• 19.1. Key Assumptions and Methodology
• 19.2. Global Rare Kidney Disease Market: Historical Trends and Forecasted Estimates, till 2040
  • 19.2.1. Comparison with Previous Edition
  • 19.2.2. Multivariate Scenario Analysis
    • 19.2.2.1. Conservative Scenario
    • 19.2.2.2. Optimistic Scenario
• 19.3. Key Market Segmentations

20. RARE KIDNEY DISEASE MARKET, BY TARGET DISEASE INDICATION

• 20.1. Rare Kidney Disease Market: Distribution by Target Disease Indication
  • 20.1.1. Rare Kidney Disease Market for Lupus Nephritis: Historical Trends and Forecasted Estimates, till 2040
  • 20.1.2. Rare Kidney Disease Market for Immunoglobulin A Nephropathy: Historical Trends and Forecasted Estimates, till 2040
  • 20.1.3. Rare Kidney Disease Market for Fabry Disease: Historical Trends and Forecasted Estimates, till 2040
  • 20.1.4. Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome: Historical Trends and Forecasted Estimates, till 2040
  • 20.1.5. Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis: Historical Trends and Forecasted Estimates, till 2040
  • 20.1.6. Rare Kidney Disease Market for Others: Historical Trends and Forecasted Estimates, till 2040

21. RARE KIDNEY DISEASE MARKET, BY TYPE OF MOLECULE

• 21.1. Rare Kidney Disease Market: Distribution by Type of Molecule
  • 21.1.1. Rare Kidney Disease Market for Small Molecules: Historical Trends and Forecasted Estimates, till 2040
  • 21.1.2. Rare Kidney Disease Market for Biologics: Historical Trends and Forecasted Estimates, till 2040

22. RARE KIDNEY DISEASE MARKET, BY TYPE OF BIOLOGIC

• 22.1. Rare Kidney Disease Market: Distribution by Type of Biologic
  • 22.1.1. Rare Kidney Disease Market for Monoclonal Antibodies: Historical Trends and Forecasted Estimates, till 2040
  • 22.1.2. Rare Kidney Disease Market for Enzymes: Historical Trends and Forecasted Estimates, till 2040
  • 22.1.3. Rare Kidney Disease Market for Proteins: Historical Trends and Forecasted Estimates, till 2040
  • 22.1.4. Rare Kidney Disease Market for Hormones: Historical Trends and Forecasted Estimates, till 2040

23. RARE KIDNEY DISEASE MARKET, BY ROUTE OF ADMINISTRATION

• 23.1. Rare Kidney Disease Market: Distribution by Route of Administration
  • 23.1.1. Rare Kidney Disease Market for Oral Route: Historical Trends and Forecasted Estimates, till 2040
  • 23.1.2. Rare Kidney Disease Market for Intravenous Route: Historical Trends and Forecasted Estimates, till 2040
  • 23.1.3. Rare Kidney Disease Market for Subcutaneous Route: Historical Trends and Forecasted Estimates, till 2040

24. RARE KIDNEY DISEASE MARKET, BY TYPE OF THERAPY

• 24.1. Rare Kidney Disease Market: Distribution by Type of Therapy
  • 24.1.1. Rare Kidney Disease Market for Monotherapy: Historical Trends and Forecasted Estimates, till 2040
  • 24.1.2. Rare Kidney Disease Market for Combination Therapy: Historical Trends and Forecasted Estimates, till 2040

25. RARE KIDNEY DISEASE MARKET, BY KEY GEOGRAPHICAL REGIONS

• 25.1. Rare Kidney Disease Market: Distribution by Key Geographical Regions
  • 25.1.1. Rare Kidney Disease Market in North America: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.1.1. Rare Kidney Disease Market in the US: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.1.2. Rare Kidney Disease Market in Canada: Historical Trends and Forecasted Estimates, till 2040
  • 25.1.2. Rare Kidney Disease Market in Europe: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.2.1. Rare Kidney Disease Market in Germany: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.2.2. Rare Kidney Disease Market in UK: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.2.3. Rare Kidney Disease Market in Spain: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.2.4. Rare Kidney Disease Market in France: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.2.5. Rare Kidney Disease Market in the Italy: Historical Trends and Forecasted Estimates, till 2040
  • 25.1.3. Rare Kidney Disease Market in Asia-Pacific: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.3.1. Rare Kidney Disease Market in China: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.3.2. Rare Kidney Disease Market in India: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.3.3. Rare Kidney Disease Market in South Korea: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.3.4. Rare Kidney Disease Market in Japan: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.3.5. Rare Kidney Disease Market in Australia: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.3.6. Rare Kidney Disease Market in Taiwan: Historical Trends and Forecasted Estimates, till 2040

26. RARE KIDNEY DISEASE MARKET, SALES FORECAST OF DRUGS

• 26.1. Approved Rare Kidney Disease Drugs / Therapies: Sales Forecast
  • 26.1.1. Benlysta(R): Sales Forecast
  • 26.1.2. Elfabrio(R): Sales Forecast
  • 26.1.3. FILSPARI(R): Sales Forecast
  • 26.1.4. Galafold(R): Sales Forecast
  • 26.1.5. LUPKYNIS(R): Sales Forecast
  • 26.1.6. Sibnayal(R): Sales Forecast
  • 26.1.7. Tarpeyo(R): Sales Forecast
  • 26.1.8. TERLIVAZ(R): Sales Forecast
  • 26.1.9. ULTOMIRIS(R): Sales Forecast
• 26.2. Phase III Rare Kidney Disease Drugs / Therapies: Sales Forecast
  • 26.2.1. ALPN-303 (Immunoglobulin A Nephropathy): Sales Forecast
  • 26.2.2. APL-2 (C3 Glomerulopathy): Sales Forecast
  • 26.2.3. APL-2 (Membranous Nephropathy): Sales Forecast
  • 26.2.4. Atacicept (Immunoglobulin A Nephropathy): Sales Forecast
  • 26.2.5. Atacicept (Lupus Nephritis): Sales Forecast
  • 26.2.6. Atrasentan (Immunoglobulin A Nephropathy): Sales Forecast
  • 26.2.7. Crovalimab (Atypical Hemolytic Uremic Syndrome): Sales Forecast
  • 26.2.8. FILSPARI(R) (Focal Segmental Glomerulosclerosis): Sales Forecast
  • 26.2.9. Ianalumab (Lupus Nephritis): Sales Forecast
  • 26.2.10. Iptacopan (Atypical Hemolytic Uremic Syndrome): Sales Forecast
  • 26.2.11. Iptacopan (C3 Glomerulopathy): Sales Forecast
  • 26.2.12. Iptacopan (Immunoglobulin A Nephropathy): Sales Forecast
  • 26.2.13. Lucerastat (Fabry Disease): Sales Forecast
  • 26.2.14. MIL62 (Membranous Nephropathy): Sales Forecast
  • 26.2.15. Obinutuzumab (Nephrotic Syndrome): Sales Forecast
  • 26.2.16. Obinutuzumab (Membranous Nephropathy): Sales Forecast
  • 26.2.17. Obinutuzumab (Lupus Nephritis): Sales Forecast
  • 26.2.18. Repagermanium (Focal Segmental Glomerulosclerosis): Sales Forecast
  • 26.2.19. Saphnelo(TM) (Lupus Nephritis): Sales Forecast
  • 26.2.20. Sibeprenlimab (Immunoglobulin A Nephropathy): Sales Forecast
  • 26.2.21. SNP-ACTH (Membranous Nephropathy): Sales Forecast
  • 26.2.22. Telitacicept (Immunoglobulin A Nephropathy): Sales Forecast
  • 26.2.23. Tolvaptan (Autosomal Recessive Polycystic Kidney Disease): Sales Forecast
  • 26.2.24. ULTOMIRIS(R) (Immunoglobulin A Nephropathy): Sales Forecast
  • 26.2.25. Venglustat (Fabry Disease): Sales Forecast
  • 26.2.26. Zigakibart (Immunoglobulin A Nephropathy): Sales Forecast

27. RARE KIDNEY DISEASE MARKET, BY LEADING DRUG DEVELOPERS

SECTION VII: OTHER EXCLUSIVE INSIGHTS

28. CONCLUDING INSIGHTS

29. INSIGHTS FROM PRIMARY RESEARCH

SECTION VIII: APPENDICES

30. TABULATED DATA

31. LIST OF COMPANIES AND ORGANIZATIONS

관련자료